Sponsors (4)
The bill strengthens biosecurity by funding standards and convening stakeholders to reduce risks from synthesized sequences, but it imposes compliance burdens, raises privacy concerns, and may be underfunded relative to the scope and evolving nature of the risks.
Hospitals, public-health agencies, and state governments will face a lower risk of synthesized harmful genetic material entering diagnostics, therapeutics, and related supply chains because the bill supports development of stronger screening standards and measurement tools.
Researchers and DNA-synthesis companies will have standardized best practices and measurement tools to improve the accuracy and reliability of nucleic acid synthesis screening, reducing accidental or malicious synthesis risks.
Scientists, researchers, and students gain predictable federal support (authorized $5M/year for FY2026–2030) for NIST measurement science and standards development that accelerates biosecurity tool development and validation.
Small DNA-synthesis manufacturers and other smaller providers will likely incur additional compliance and conformity-assessment costs to meet new screening standards.
Researchers and commercial customers may face proprietary and privacy risks because increased screening and data-sharing around sequences-of-concern could expose unpublished sequences or business-sensitive information.
The authorized funding level ($5M/year) may be insufficient to fully carry out the measurement research and standards development needed across the industry, slowing implementation and diminishing expected benefits.
Based on analysis of 2 sections of legislative text.
Directs NIST to do research, convene stakeholders, develop standards for nucleic acid synthesis screening (including AI risks), report to Congress, and authorizes $5M/year for FY2026–2030.
Requires the National Institute of Standards and Technology (NIST) to lead research, convene stakeholders, and develop standards, best practices, and measurement methods for screening and managing risks from synthetic nucleic acids, including risks tied to artificial intelligence. Directs NIST to produce a report within 18 months of the first consortium meeting and authorizes $5 million per year for FY2026–2030 to support the research and related activities.
Official title: To amend the Research and Development, Competition, and Innovation Act to support nucleic acid screening, and for other purposes.
Introduced April 28, 2025 by Andrea Salinas · Last progress July 20, 2026